Skip to main content
SpringerLink
Log in

The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The pharmacologic management of atrial fibrillation (AF) includes rate and rhythm control strategies. Antiarrhythmic agents (eg, amiodarone, flecainide, and propafenone) are limited by serious toxicities (including proarrhythmic effects and pulmonary toxicity), which may lead to a reduced net clinical efficacy of rhythm control strategies. Dronedarone, a new antiarrhythmic agent, is effective in the maintenance of sinus rhythm. Dronedarone has also been shown to reduce ventricular rate and the incidence of hospitalization due to cardiovascular events. Dronedarone is recommended by the 2011 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society guidelines update for the management of AF patients with no or minimal heart disease, coronary artery disease, and hypertension with no left ventricular hypertrophy. Dronedarone is contraindicated in patients with New York Heart Association (NYHA) class IV heart failure or NYHA class II–III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534–1539.

    Article  PubMed  Google Scholar 

  2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–2375.

    Article  PubMed  CAS  Google Scholar 

  3. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101–e198.

    Article  PubMed  Google Scholar 

  4. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis. 2005;48:1–8.

    Article  PubMed  Google Scholar 

  5. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–364.

    Article  PubMed  Google Scholar 

  6. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–356.

    Article  PubMed  Google Scholar 

  7. Kim MH, Lin J, Hussein M, Battleman D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin. 2009;25:1215–1220.

    Article  PubMed  CAS  Google Scholar 

  8. Patel PP, Johnston SJ, Lin J, Schulman KL, Naccarelli GV. Cost burden of hospitalization and mortality in United States atrial fibrillation/flutter patients (abstract PO03-53). Presented at: Heart Rhythm; May 13–16, 2009; Boston, MA.

  9. Kim MH, Lin J, Hussein M, Kreilick C, Battleman D. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009;26:1–11.

    Google Scholar 

  10. Kim MH, Klingman D, Lin J, Pathak P, Battleman DS. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother. 2009;43:840–848.

    Article  PubMed  Google Scholar 

  11. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241–247.

    Article  PubMed  Google Scholar 

  12. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303–1309.

    Article  PubMed  CAS  Google Scholar 

  13. Paquette M, Roy D, Talajic M, et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am J Cardiol. 2000;86:764–768.

    Article  PubMed  CAS  Google Scholar 

  14. Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States, 1980–1998. Am J Epidemiol. 2002;155:819–826.

    Article  PubMed  Google Scholar 

  15. Atrial fibrillation as a contributing cause of death and Medicare hospitalization — United States, 1999. MMWR Morb Mortal Wkly Rep. 2003;52:128,130–131.

  16. Hohnloser SH. New pharmacological options for patients with atrial fibrillation: the ATHENA trial. Rev Esp Cardiol. 2009;62:479–481.

    Article  PubMed  Google Scholar 

  17. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:104–123.

    Article  PubMed  Google Scholar 

  18. Michaud GF, John R. Percutaneous pulmonary vein isolation for atrial fibrillation ablation. Circulation. 2011;123:e596–e601.

    Article  PubMed  Google Scholar 

  19. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–2429.

    Article  PubMed  Google Scholar 

  20. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10:S451–S458.

    PubMed  Google Scholar 

  21. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [press release]. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed July 13, 2011.

  22. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562–2570.

    Article  PubMed  Google Scholar 

  23. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.

    Article  PubMed  CAS  Google Scholar 

  24. Food and Drug Administration. FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm [press release]. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htm. Accessed November 7, 2011.

  25. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.

    Article  PubMed  CAS  Google Scholar 

  26. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.

    Article  PubMed  CAS  Google Scholar 

  27. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.

    Article  PubMed  CAS  Google Scholar 

  28. Krishnamoorthy S, Lip GY. Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Rev Cardiovasc Ther. 2009;7:473–481.

    Article  PubMed  CAS  Google Scholar 

  29. Vidaillet H, Greenlee RT. Rate control versus rhythm control. Curr Opin Cardiol. 2005;20:15–20.

    PubMed  Google Scholar 

  30. Gopinathannair R, Sullivan RM, Olshansky B. Update on medical management of atrial fibrillation in the modern era. Heart Rhythm. 2009;6:S17–S22.

    Article  PubMed  Google Scholar 

  31. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201–1208.

    Article  PubMed  Google Scholar 

  32. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47–59.

    PubMed  CAS  Google Scholar 

  33. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1–82.

    Article  PubMed  Google Scholar 

  34. Van Gelder I, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–1373.

    Article  PubMed  Google Scholar 

  35. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol. 2006;17(Suppl. 2):S17–S20.

    Article  PubMed  Google Scholar 

  36. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–1872.

    Article  PubMed  CAS  Google Scholar 

  37. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509–1513.

    Article  PubMed  Google Scholar 

  38. Pedersen OD, Brendorp B, Elming H, Pehrson S, Kober L, Torp-Pedersen C. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev. 2003;7:220–224.

    Article  PubMed  Google Scholar 

  39. Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med. 2003;139:1009–1017.

    PubMed  Google Scholar 

  40. Kim MH, Klingman D, Lin J, Battleman DS. Patterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillation. Pharmacotherapy. 2009;29:1417–1426.

    Article  PubMed  Google Scholar 

  41. Prystowsky EN. Atrial fibrillation: dronedarone and amiodarone-the safety versus efficacy debate. Nat Rev Cardiol. 2010;7:5–6.

    Article  PubMed  CAS  Google Scholar 

  42. Pacerone [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2008.

  43. Cordarone [package insert]. Philadelphia, PA: Wyeth Laboratories; 2004.

  44. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913–920.

    Article  PubMed  CAS  Google Scholar 

  45. Kopelman HA, Horowitz LN. Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis. 1989;31:355–366.

    Article  PubMed  CAS  Google Scholar 

  46. Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250–1259.

    Article  PubMed  Google Scholar 

  47. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet. 1997;350:1417–1424.

  48. Kim MH, Lin J, Hussein M, Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009;25:3037–3047.

    Article  PubMed  CAS  Google Scholar 

  49. Ishak KJ, Proskorovsky I, Guo S, Lin J. Persistence with antiarrhythmics and the impact on atrial fibrillation-related outcomes. Am J Pharm Benefits. 2009;1:193–200.

    Google Scholar 

  50. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–1833.

    Article  PubMed  CAS  Google Scholar 

  51. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19:1220–1226.

    Article  PubMed  Google Scholar 

  52. Multaq [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2011.

  53. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329–345.

    Article  PubMed  Google Scholar 

  54. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–999.

    Article  PubMed  CAS  Google Scholar 

  55. Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527–529.

    Article  PubMed  Google Scholar 

  56. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–2687.

    Article  PubMed  Google Scholar 

  57. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–678.

    Article  PubMed  CAS  Google Scholar 

  58. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–605.

    Article  PubMed  Google Scholar 

  59. Tschuppert Y, Buclin T, Rothuizen LE, et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64:785–791.

    PubMed  CAS  Google Scholar 

  60. Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011;107:1019–1022.

    Article  PubMed  CAS  Google Scholar 

  61. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174–1180.

    Article  PubMed  CAS  Google Scholar 

  62. Torp-Pedersen C, Page RL, Connolly SJ, et al. The effect of dronedarone on hospitalizations in patients with atrial fibrillation. Results from the ATHENA study [abstract 4101]. Circulation. 2008;118:S828.

    Article  Google Scholar 

  63. Sanofi-Aventis. Sanofi-Aventis initiates 10,000 patient study with Multaq® in permanent AF [press release]. Available at: www.prnewswire.com/news-releases/sanofi-aventis-initiates-10000-patient-study-with-multaqr-in-permanentaf-93551119.html. Accessed July 13, 2011.

  64. Sanofi-Aventis. Sanofi provides Multaq phase IIIb PALLAS trial update. Available at: en.sanofi.com/binaries/20110707_PALLAS_en_tcm28-33021.pdf. Accessed July 13, 2011.

  65. Food and Drug Administration. FDA drug safety communication: multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. Available at: www.fda.gov/Drugs/DrugSafety/ucm264059.htm. Accessed October 31, 2011.

  66. Food and Drug Administration. FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). Available at: www.fda.gov/Drugs/DrugSafety/ucm240011.htm. Accessed July 13, 2011.

  67. Food and Drug Administration. Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between July–September 2010. Available at: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm237585.htm. Accessed March 21, 2011.

  68. QuaterWatch: 2010 Quarter 1. Monitoring MedWatch Reports. Signals for acetaminophen, dronedarone and botulinum toxin products [executive summary]. Available at: freepdfhosting.com/078147c86d.pdf. Accessed March 21, 2011.

  69. Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol. 2010;33:270–279.

    Article  PubMed  Google Scholar 

  70. European Medicines Agency. European Medicines Agency recommends restricting use of multaq. Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/09/news_detail_001344.jsp&murl=menus/news_and_events/news_and_events.jsp&jsenabled=true. Accessed November 3, 2011.

Download references

Author information

Authors and Affiliations

  1. Cardiac Cath Laboratory, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ, 07112, USA

    Marc Cohen & Catalin Boiangiu

Authors
  1. Marc Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catalin Boiangiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Cohen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, M., Boiangiu, C. The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy. Adv Therapy 28, 1059–1077 (2011). https://doi.org/10.1007/s12325-011-0086-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0086-1

Keywords

Search

Navigation